Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1463 other investors.
Redeye regards Genovis’ Q2’21 report as solid and finds it encouraging to see continued high growth in the core Analytics segment.
In this note, Redeye elaborates on why we see the cross-licensing agreement with GlycoT Therapeutics as strategically interesting.
Under the agreements, the combined proprietary technology platform will enable Genovis and GlycoT Therapeutics ("GlycoT") to market, sell and further develop enzymatic workflows for the research and diagnostics markets as well as for therapeutic applications.
The Annual General Meeting adopted the following resolutions:
The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.
The Board and the Chief Executive Officer were discharged from liability.
The Board shall consist until the next AGM of five ordinary members without deputies.
Re-election of Board membersTorben Jørgensen,Mikael Lönn, Kenth Petersson and Lotta Ljungqvist.
Steve Jordanwas elected new Board member.
Redeye provides a follow-up note to Genovis Q1'21 report, with updated estimates and valuation.
Redeye’s first impression of Genovis Q1’21 is that it is a pretty solid report in the core business, given that customer activity remains regionally sluggish due to the pandemic.
First quarter in brief
Net sales rose by 37 percent to SEK 15,723 (11,475) thousand. Organic growth was 21%.
Gross profit was SEK 15,017 (10,977) thousand.
Operating profit before depreciation and amortization (EBITDA) totaled SEK 1,958 (loss: 847) thousand.
Operating profit totaled SEK 551 (loss: 1,889) thousand.
Comprehensive income for the period totaled SEK 1,607 (loss: 1,915) thousand.
Genovis 2020 Annual Report is now available in Swedish and English at our website.
To read or download the annual report in Swedish, go to:
https://investor.genovis.com/wp-content/uploads/genovis-arsredovisning-2020.pdf
To read or download the annual report in English, go to:
https://investor.genovis.com/wp-content/uploads/genovis-annual-report-2020.pdf
The shareholders of Genovis AB, corporate identity no 556574-5345, are hereby given notice of the Annual General Meeting on Thursday, May 20, 2021.